ENDRA Life Sciences (NDRA) Total Liabilities (2016 - 2026)

ENDRA Life Sciences has disclosed Total Liabilities across 11 years of filings, most recently posting $1.7 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 16.48% year-over-year to $1.7 million; the TTM figure through Mar 2026 stood at $1.7 million (up 16.48% YoY), while the FY2025 annual figure was $1.6 million, down 15.77% from the prior year.
• Total Liabilities improved to $1.7 million in Q1 2026, from $1.6 million in the prior quarter.
• Over the last five years, Total Liabilities for NDRA reached as high as $2.4 million in Q3 2023 and fell as low as $1.1 million in Q4 2023.
• The 5-year median for Total Liabilities is $1.8 million (2025), against an average of $1.8 million.
• Annual changes were most pronounced in 2022 — Total Liabilities surged 78.48% — and 2023, when it plunged 47.08%.
• A 5-year view of Total Liabilities shows it stood at $2.1 million in 2022, then slumped by 47.08% to $1.1 million in 2023, then surged by 72.76% to $1.9 million in 2024, then decreased by 15.77% to $1.6 million in 2025, then climbed by 3.62% to $1.7 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $1.7 million, $1.6 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.